Robert Manges

1.2k total citations
21 papers, 730 citations indexed

About

Robert Manges is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Robert Manges has authored 21 papers receiving a total of 730 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Robert Manges's work include Multiple Myeloma Research and Treatments (10 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Robert Manges is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Robert Manges collaborates with scholars based in United States, France and Netherlands. Robert Manges's co-authors include Philip J. Stella, Herbert I. Hurwitz, William M. Garrett, Deborah Hunter, J. Marc Pipas, Jason Clark, Lance Leopold, Johanna C. Bendell, Victor Sandor and Nikhil Uppal and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Robert Manges

21 papers receiving 717 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Manges United States 9 566 227 190 162 135 21 730
Hong Xie United States 13 406 0.7× 338 1.5× 252 1.3× 65 0.4× 138 1.0× 29 739
Christoph Heining Germany 9 246 0.4× 240 1.1× 183 1.0× 118 0.7× 43 0.3× 29 567
Lawrence Garbo United States 15 427 0.8× 311 1.4× 71 0.4× 84 0.5× 74 0.5× 35 741
T Yoshikubo Japan 9 453 0.8× 168 0.7× 90 0.5× 174 1.1× 127 0.9× 16 765
Pamela Lockbaum United States 9 763 1.3× 167 0.7× 208 1.1× 63 0.4× 93 0.7× 13 983
Tahir Latif United States 13 214 0.4× 211 0.9× 133 0.7× 70 0.4× 50 0.4× 38 588
H. J. Illiger Germany 11 555 1.0× 386 1.7× 172 0.9× 154 1.0× 62 0.5× 28 974
Bin Meng China 18 334 0.6× 245 1.1× 57 0.3× 141 0.9× 136 1.0× 62 814
Kenichi Harano Japan 14 401 0.7× 115 0.5× 60 0.3× 90 0.6× 68 0.5× 70 702
Ewa Matczak United States 13 295 0.5× 282 1.2× 249 1.3× 147 0.9× 112 0.8× 24 866

Countries citing papers authored by Robert Manges

Since Specialization
Citations

This map shows the geographic impact of Robert Manges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Manges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Manges more than expected).

Fields of papers citing papers by Robert Manges

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Manges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Manges. The network helps show where Robert Manges may publish in the future.

Co-authorship network of co-authors of Robert Manges

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Manges. A scholar is included among the top collaborators of Robert Manges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Manges. Robert Manges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nowakowski, Grzegorz S., Wolfgang Willenbacher, Richard Greil, et al.. (2021). Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. International Journal of Hematology. 115(2). 222–232. 17 indexed citations
2.
Nowakowski, Grzegorz S., Wolfgang Willenbacher, Richard Greil, et al.. (2019). Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.. Journal of Clinical Oncology. 37(15_suppl). 7520–7520. 10 indexed citations
3.
Nowakowski, Grzegorz S., Wolfgang Willenbacher, Richard Greil, et al.. (2019). SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL. Hematological Oncology. 37(S2). 132–134. 7 indexed citations
4.
Berenson, James R., Robert Manges, Suprith Badarinath, et al.. (2017). A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. American Journal of Hematology. 92(5). 460–466. 13 indexed citations
5.
Tempero, Margaret A., Lisa M. Coussens, Lawrence Fong, et al.. (2016). A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).. Journal of Clinical Oncology. 34(15_suppl). TPS2601–TPS2601. 8 indexed citations
6.
7.
Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, et al.. (2015). Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology. 33(34). 4039–4047. 237 indexed citations
8.
Berdeja, Jesús G., Sundar Jagannath, Jeffrey A. Zonder, et al.. (2015). Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. Clinical Lymphoma Myeloma & Leukemia. 16(3). 129–138. 60 indexed citations
9.
Hurwitz, H., Nikhil Uppal, J. C. Bendell, et al.. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 25. ii115–ii115. 2 indexed citations
10.
Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, et al.. (2014). A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 32(15_suppl). 4000–4000. 35 indexed citations
11.
12.
Rougier, Philippe, Hanno Riess, Robert Manges, et al.. (2013). Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. European Journal of Cancer. 49(12). 2633–2642. 145 indexed citations
13.
Voorhees, Peter M., Robert Manges, Pieter Sonneveld, et al.. (2013). A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 161(3). 357–366. 129 indexed citations
14.
Mahesh, Sameer, Nashat Gabrail, Alok A. Khorana, et al.. (2013). Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in combination with gemcitabine in patients with advanced pancreatic cancer.. Journal of Clinical Oncology. 31(15_suppl). e15014–e15014. 1 indexed citations
15.
Modiano, Manuel, George P. Keogh, Robert Manges, et al.. (2012). Apricot-P: A randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas.. Journal of Clinical Oncology. 30(4_suppl). 253–253. 7 indexed citations
16.
Manges, Robert, Pieter Sonneveld, Sundar Jagannath, et al.. (2011). A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,. Blood. 118(21). 3971–3971. 8 indexed citations
17.
18.
Rossi, Jean‐François, Robert Manges, Heather J. Sutherland, et al.. (2008). Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. Blood. 112(11). 867–867. 23 indexed citations
19.
Voorhees, Peter M., Robert Manges, Pieter Sonneveld, et al.. (2008). Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology. 26(15_suppl). 8593–8593. 3 indexed citations
20.
Manges, Robert, Heather J. Sutherland, Sundar Jagannath, et al.. (2007). Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.. Blood. 110(11). 1183–1183. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hong Xie Breakdown of academic impact, for papers by Christoph Heining Breakdown of academic impact, for papers by Lawrence Garbo Breakdown of academic impact, for papers by T Yoshikubo Breakdown of academic impact, for papers by Pamela Lockbaum Breakdown of academic impact, for papers by Tahir Latif Breakdown of academic impact, for papers by H. J. Illiger Breakdown of academic impact, for papers by Bin Meng Breakdown of academic impact, for papers by Kenichi Harano Breakdown of academic impact, for papers by Ewa Matczak
Rankless by CCL
2026